4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-020476
CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $26.70 ($320,378)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-07-29 | Sale : show line 1 in the form 10b5-1 | −11,797 | $26.69 | $314,809 | 1,093,238 | I |
| 2024-07-29 | Sale : show line 2 in the form 10b5-1 | −203 | $27.43 | $5,569 | 1,093,035 | I |
| Open-market sales · 12,000 sh · avg $26.70 · $320,378 | ||||||
Loading xslF345X05/form4-07312024_110752.xml…